A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects |
| |
Authors: | Keefer Michael C Frey Sharon E Elizaga Marnie Metch Barbara De Rosa Stephen C Barroso Paulo F Tomaras Georgia Cardinali Massimo Goepfert Paul Kalichman Artur Philippon Valérie McElrath M Juliana Jin Xia Ferrari Guido Defawe Olivier D Mazzara Gail P Montefiori David Pensiero Michael Panicali Dennis L Corey Lawrence;NIAID HIV Vaccine Trials Network |
| |
Institution: | Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. Michael Keefer@urmc.rochester.edu |
| |
Abstract: | We evaluated replication-defective poxvirus vectors (modified vaccinia Ankara MVA] and fowlpox FPV]) in a homologous and heterologous vector prime-boost vaccination regimen containing matching HIV inserts (MVA-HIV and FPV-HIV) given at months 0, 1, 3, 5 and 7 in 150 healthy HIV-negative vaccinia-na?ve participants. FPV-HIV alone was poorly immunogenic, while the high dose (10(9)pfu/2 ml) of MVA-HIV alone elicited maximal responses after two injections: CD4+ and CD8+ T-cell responses in 26/55 (47.3%) and 5/60 (8.3%) of participants, respectively, and IFN-γ ELISpot responses in 28/62 (45.2%). The infrequent CD8+ T-cell responses following MVA-HIV priming were boosted only by the heterologous (FPV-HIV) construct in 14/27 (51.9%) of participants post 4th vaccination. Alternatively, HIV envelope-specific binding antibodies were demonstrated in approximately two-thirds of recipients of the homologous boosting regimen, but in less than 20% of subjects after the heterologous vector boost. Thus, a heterologous poxvirus vector prime-boost regimen can induce HIV-specific CD8+ T-cell and CD4+ T-cell responses, which may be an important feature of an optimal regimen for preventive HIV vaccination. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|